Purchase this article with an account.
C-C Lai, W-C Wu, S-L Chen, X Xiao, T-C Tsai, S-J Huan, T-L Chen, R-F Tsai, Y-P Tsao; Suppression of Preretinal Neovascularization by Recombinant Adeno-associated Virus Expressing Angiostatin . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1269.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To test the efficacy of recombinant adeno-associated virus (rAAV) vector expressing mouse angiostatin in suppressing experimental preretinal neovascularization in an albino rat model. Methods: rAAV-angiostatin and control virus rAAV-lacZ were delivered in vivo by intravitreous injection on Sprague-Dawley rats and the delivery was confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR). For suppression of preretinal neovascularization, preretinal neovascularization was created by retinal vein occlusion 21 days after the injection. The retinal vein occlusion was induced by photodynamic therapy with systemic injection of rose bengal (40mg/kg) followed by an argon green laser. The animals were sacrificed 10 days after the retinal vein thrombosis and perfused with FITC-labelled dextran to serve as neovascularization analysis. After perfusion, those samples with evidence of neovascularization were quantified using an image analyzer. The retinas were also embedded in paraffin and serially sectioned at 6µm. The samples were stained with hematoxylin and eosin. Nuclei above the internal limiting membrane were then count in a masked manner. Results: The sizes of preretinal neovascularization in rAAV-angiostatin injected eyes were significantly smaller than the controlled eyes. Moreover, the number of vitreous cells was also less in experimental eyes. Conclusion: rAAV-angiostatin can successfully suppress the experimental preretinal neovascularization in albino rats. The results showed the feasibility of gene therapy approach as treatment of preretinal neovascularization.
This PDF is available to Subscribers Only